Several experimental studies and meta-analysis reported that EGFR-tyrosine kinase inhibitors (EGFR-TKIs) treatment has better efficacy in advanced stage of NSCLC with these EGFR mutation positive compared with conventional chemotherapy treatment[6-9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.